NVAX has received solid support in the buy zone ($6.50-$7) throughout Q3. I think NVAX will have its breakout in Q4 and the key resistance targets are the $16.21 and $23.13 price levels. October will be an important month for NVAX with the European Union deciding whether to approve the NVAX COVID vaccine. Germany already has an interest in placing an order for 10.6 million vaccine doses in Q4 if NVAX does receive approval.